Published in final edited form as:

J Alzheimers Dis. 2012 ; 32(3): 599–608. doi:10.3233/JAD-2012-120820.

Fibrinogen and Altered Hemostasis in Alzheimer's Disease

Marta Cortes-Canteli, Daria Zamolodchikov, Hyung Jin Ahn, Sidney Strickland, and Erin H. Norris*

Laboratory of Neurobiology and Genetics, The Rockefeller University, New York, NY 10065, USA

Abstract

Alzheimer's disease (AD) is characterized by amyloid- β (A β) plaques, tau tangles, brain atrophy, and vascular pathology. Vascular defects include cerebrovascular dysfunction, decreased cerebral blood flow, and blood brain barrier (BBB) disruption, among others. Here, we review the evidence that links A β with the vascular pathology present in AD, with a specific focus on the hemostatic system and the clotting protein fibrinogen. Fibrinogen is normally found circulating in blood, but in AD it deposits with A β in the brain parenchyma and cerebral blood vessels. We found that A β and fibrin(ogen) interact, and their binding leads to increased fibrinogen aggregation, A β fibrillization, and the formation of degradation-resistant fibrin clots. Decreasing fibrinogen levels not only lessens cerebral amyloid angiopathy (CAA) and BBB permeability, but it also reduces microglial activation and improves cognitive performance in AD mouse models. Moreover, a prothrombotic state in AD is evidenced by increased clot formation, decreased fibrinolysis, and elevated levels of coagulation factors and activated platelets. Abnormal deposition and persistence of fibrin(ogen) in AD may result from A β -fibrin(ogen) binding and altered hemostasis and could thus contribute to A β deposition, decreased cerebral blood flow, exacerbated neuroinflammation, and eventual neurodegeneration. Blocking the interaction between fibrin(ogen) and A β may be a promising therapeutic target for AD.

Keywords

Fibrinogen; hemostasis; thrombosis; blood brain barrier; cerebral amyloid angiopathy; blood coagulation

Alzheimer's disease (AD), a debilitating and fatal cognitive disorder that currently affects over 26 million people worldwide, is a severe neurodegenerative disease characterized by A β plaques, tau tangles, and brain atrophy. Accumulating evidence also links AD with vascular risk factors [1]. These correlations, together with profound alterations of cerebrovascular structure and function present in AD [2], suggest a "vascular hypothesis", where vascular pathology eventually leads to neurodegeneration and subsequent cognitive decline [3, 4]. Neuronal dysfunction may also be caused by the accumulation of A β , known as the "amyloid hypothesis" [5]. Here, we review the evidence that connects vascular disease and AD, focusing specifically on how the clotting protein fibrin(ogen) could be the missing link between the vascular and amyloid hypotheses [6].

Fibrin(ogen) in AD

Fibrinogen is a 340 kDa plasma glycoprotein that plays a key role in coagulation. Upon cleavage by thrombin, fibrinogen is converted to fibrin, which polymerizes into a fibrin

*Corresponding author: Erin H. Norris, PhD, The Rockefeller University, Laboratory of Neurobiology and Genetics, 1230 York Avenue, New York, NY 10065, Phone: 212-327-8707, Fax: 212-327-8774, enorris@rockefeller.edu.

network, or clot [7]. Fibrinogen further contributes to hemostasis by forming bridges between activated platelets and promoting their aggregation [8]. Fibrin clot lysis is mediated by plasmin, which is generated from plasminogen on the fibrin surface following activation by tissue plasminogen activator (tPA). In addition to its role in coagulation, fibrinogen has adhesive and inflammatory functions mediated by its interactions with numerous proteins in the circulation and on cell surfaces [7].

Due to its key role in hemostasis, changes in the levels of fibrinogen can have serious pathological consequences. Elevated levels of plasma fibrinogen lead to increased blood viscosity, platelet and endothelial cell activation, erythrocyte aggregation, and reduced blood flow [9], predisposing people to cardiovascular disease and stroke [10]. Interestingly, the analysis of plasma from large cohorts of patients showed that elevated fibrinogen levels are associated with cognitive decline [11], increased risk of AD [12], and brain atrophy in AD patients [13], suggesting a link between an abnormal clotting system and cognitive deficits.

Fibrin(ogen), BBB dysfunction, and CAA formation

Fibrin(ogen) is normally excluded from the brain by the BBB, but it has been detected in the brains of AD patients and mouse models [14–20]. BBB dysfunction has been reported in brains of AD mice [18, 21] and humans [19, 20, 22], which may explain the extravasation of fibrin(ogen), and thus its presence, in the brain parenchyma. This movement of fibrin(ogen) through the BBB appears to be rather specific, since some smaller molecules are not BBB-permeable in this disorder [23, 24]. BBB dysfunction may be initially induced by vascular factors currently connected with AD [1], including ischemia [25], ingestion of saturated fats or cholesterol [26], inflammation processes in the brain [27], or hypertensive crises [28]. Another possible mechanism for BBB malfunction in AD could be the increased deposition of fibrin(ogen). *In vitro*, pathologically high levels of fibrinogen can promote microvascular permeability by decreasing levels of endothelial tight junction proteins [29, 30], which could in turn contribute to the accumulation of fibrin(ogen) outside the circulation. A third mechanism for BBB disruption in AD could be the presence of CAA, deposits of A β in cortical and leptomeningeal vessel walls of arteries, arterioles, and capillaries, which can result from the incomplete or improper clearance of A β from the brain parenchyma [31, 32]. CAA-positive vessels exhibit smooth muscle cell loss, vessel wall remodeling [33, 34], and occlusions [35]. These changes could lead to blood vessel weakening and BBB dysfunction, which may contribute to the increased occurrence of cerebral microbleeds, hemorrhages, and infarcts typical of CAA [33, 34, 36]. These processes can in turn impede cerebral blood flow and reduce blood supply to the brain, leading to the hypoperfusion observed in AD patients [37, 38]. This evidence clearly suggests that the CAA-impaired vasculature can significantly impact brain function.

We and others have reported that CAA-positive vessels in the brains of AD mice and patients also contain fibrin(ogen) deposits [14, 39] (Figure). To determine if fibrin(ogen) affects the accumulation of A β in the vasculature, we decreased fibrinogen levels in two AD mouse models either genetically or pharmacologically. The total amount of CAA was significantly diminished [14], suggesting that fibrinogen directly affects the deposition and clearance of A β deposits in the brain vasculature. More importantly, we also found that AD mice with reduced fibrinogen levels in their blood showed significant improvement in spatial memory [14].

Interaction between fibrin(ogen) and A β

Since fibrin(ogen) and A β co-deposit in the AD brain [14, 16, 18–20, 39] (Figure), we hypothesized that A β and fibrinogen could physically interact. We found that fibrinogen binds to A β *in vitro* ($K_d = 26.3 \pm 6.7$ nM), which enhances fibrinogen aggregation and

increases A β fibrillization [40]. It is thus possible that the development of CAA is accelerated when A β encounters fibrin(ogen) in the vessel wall. In agreement with this hypothesis, mice subjected to ischemic lesioning showed rapid increases in A β deposition in the vessels and parenchyma near the infarcted area [41], which could be due to improper clearance of A β through the vasculature. These lesions, which involve the production of fibrin, may also induce A β aggregation and deposition following fibrin(ogen) extravasation through a dysfunctional BBB.

Thrombotic/Fibrinolytic System in AD

Abnormal clot formation and degradation in AD

We have shown that the presence of A β affects the structure of fibrin clots and interferes with clot lysis *in vitro* [14, 42]. Our *in vivo* experiments also demonstrate that AD mice have an increased propensity to clot, and the resulting thrombi are more resistant to degradation than clots formed in controls [14]. Similar results were obtained by Klohs *et al.*, who examined vascular function in a mouse model of CAA [39]. A significant reduction in the number of functional intracortical microvessels in aged CAA mice compared to control littermates was observed, which was attributed to obstructed perfusion resulting from abnormal fibrin clot lysis. Fibrinogen and CAA co-deposited in the vessels of these mice, which could suggest that vessel obstruction results from the formation of persistent A β -laden fibrin clots. *In vitro* studies suggest that the delay in fibrin clot lysis in AD could partially be due to the formation of a tighter fibrin network in the presence of A β and to the interference of A β with the binding of plasminogen to fibrin [42]. Another possibility could be a delay in the *in vivo* recanalization process that involves extravasation of emboli into the perivascular parenchyma, which slows with age [43]. Fibrin(ogen) deposits and clots in AD cerebral vessels could thus be rendered more persistent through their interaction with A β , which could initiate and/or aggravate brain hypoperfusion and inflammation.

Anticoagulant therapy as treatment for AD?

Studies of anticoagulant treatment in AD mice and patients provide another link between AD and the hemostatic abnormalities observed in this disease. A β accumulation and A β -induced cytotoxicity were reduced [44] and spatial memory was improved [45] after treatment of AD mice with enoxaparin, a low molecular weight heparin. In human studies, placebo-treated dementia patients showed a significant deterioration in cognition, while warfarin-treated patients did not show any change in cognitive decline [46]. In addition, unregulated studies carried out several decades ago showed that the majority of dementia patients treated with warfarin presented with improved cognition compared to untreated patients [47, 48]. Furthermore, an epidemiological study on atrial fibrillation patients showed that long-term warfarin treatment is protective against dementia [49]. These results suggest that repurposing existing anticoagulants for the treatment of AD may be beneficial. However, it is well known that anticoagulant treatment may increase the incidence of major systemic bleeding in elderly patients and that the AD brain is prone to hemorrhage due to the presence of CAA [32, 34, 36]. Recent advances in the development of effective anticoagulants with a lower risk of intracranial bleeding [50] are encouraging and may be safer for AD patients. Since it may be challenging to completely eliminate the risk of bleeding during anticoagulant use, identifying a drug that blocks the A β -fibrin(ogen) interaction, thereby preventing abnormal A β -related clot formation and degradation without affecting normal coagulation, may be an interesting alternative therapy for AD patients.

Relationship between AD and stroke

Based on our hypothesis, the A β -fibrin(ogen) interaction contributes to blood vessel occlusion, resulting in decreased cerebral blood flow and compromised neuronal viability

(Figure). This model implies the existence of a close relationship between AD physiopathology and stroke/microinfarcts. Clinical studies indicate that asymptomatic spontaneous cerebral emboli are highly correlated with AD [51] and a rapid cognitive decline [52]. Furthermore, microinfarcts are more common in AD patients compared with non-demented controls [53]. Another group has shown that cerebral infarcts significantly decrease the cognitive function of patients [54]. Thus, not only may stroke increase the risk of developing dementia [55], but AD patients also demonstrate a greater risk for stroke [56]. It is possible that the overlap between these two disorders could be explained by the increased formation and persistence of occlusive fibrin clots, resulting from the A β -fibrin(ogen) interaction and altered levels of prothrombotic and fibrinolytic factors (discussed below).

Prothrombotic state in AD

A number of studies suggest that AD patients may have an enhanced potential for thrombosis in the circulation. The coagulation cascade involves the sequential activation of a series of factors, leading to the production of thrombin which mediates the final step of the coagulation cascade - the conversion of fibrinogen to fibrin. A prothrombotic state is induced when excessive quantities of thrombin are formed as a result of dysregulated hemostasis [57]. Elevated levels of activated factors VII and V (among others) contribute to a hypercoagulable state by promoting thrombin generation. Increased levels of activated factor VII were found in the plasma [58] and serum [59] of AD patients. Furthermore, carriers of factor V Leiden, a mutant form of factor V that is more resistant to inactivation and thus has increased thrombotic tendency, have an increased risk for dementia [60]. Elevated levels of von Willebrand Factor (vWF), which mediates the adhesion of platelets to wound sites and activates platelets [61], have been found in AD patient plasma [58] and serum [59]. Older adults with increased D-dimer and prothrombin fragment 1+2 levels, both markers of increased thrombin generation, are at higher risk for future cognitive decline [62], and prothrombin fragment 1+2 levels are increased in AD patient serum [59]. Increased thrombin generation in AD patients could result in unnecessary coagulation and could also contribute to the formation of abnormally structured fibrin clots that are resistant to degradation [63].

The AD brain parenchyma can also be characterized as a prothrombotic environment. Elevated levels of prothrombin [22] and thrombin [64, 65] have been found in microvessel walls and the surrounding neuropil in the AD brain. Thus, increased levels of fibrinogen extravasating into the AD vessel wall and brain parenchyma through a dysfunctional BBB would be converted to fibrin, which could be abnormally stable due to increased levels of thrombin found in AD. Fibrin stability may be further enhanced by the deficiency of fibrinolytic enzymes in the AD brain parenchyma. Decreased levels of plasmin [66], decreased tPA activity [67], and increased levels of plasminogen activation inhibitors [67, 68] have been detected in the brains of AD mice and patients. The elevated levels of A β found in the AD brain could also contribute to fibrin persistence, since A β intercalates into polymerizing fibrin and slows clot degradation [14, 42]. Thus, it is possible that A β contributes to the prothrombotic state in AD by binding to fibrinogen and altering fibrin clotting. It remains to be determined if A β affects other hemostatic factors, which may further contribute to the hypercoagulable state observed in this disorder.

Platelets in AD

Platelets are an essential part of the hemostatic response to injury, forming a platelet plug in the presence of fibrin in response to vascular damage. Platelets circulate in an inactive form, but can aggregate following activation by various signals. Increased levels of activated platelets have been found in AD patients [69, 70]. Furthermore, levels of coated platelets, a

highly pro-coagulant subset of activated platelets [71], correlate with AD severity [72, 73]. Platelets of AD patients produce more A β compared to controls [74], which is released into the circulation upon platelet activation. Because platelets become activated at sites of injury and clot formation, AD patients' platelets might deliver A β directly to clots as they are forming. *In vitro* and *in vivo* experiments have demonstrated that fibrin clots are more difficult to degrade in the presence of A β [14, 42], suggesting a mechanism by which platelets releasing increased levels of A β in AD could contribute to enhanced thrombosis.

Cross-talk between Inflammation and Hemostasis in AD

Many neurodegenerative diseases present a strong inflammatory component associated with their pathology [75]. The immune response in these pathologies is considered a double-edged sword -it is a way for the body to clear unwanted material, yet deleterious effects can occur as a result of a sustained and chronic inflammatory response. Since the cross-talk between coagulation and inflammation plays a fundamental role *in vivo* [76], we focus our discussion on the AD-related associations between hemostasis, the activation of the complement system, and microglial cells.

Relationship between the complement and coagulation cascades in AD

The complement system helps antibodies and phagocytic cells clear pathogens from the body and is thought to play an important role in the pathogenesis of AD [77, 78], since *in vitro* as well as *in situ* evidence shows that A β [79] and tau [80] are potent activators of the complement pathway. Complement proteins co-localize in the human AD brain with neurofibrillary tangles, plaques [77, 81], and dystrophic neurites [82]. There is bidirectional cross-talk between the complement and hemostatic systems. On one hand, since some complement proteins are substrates for several coagulation factors [83], increased levels of coagulation factors present in the AD brain and circulation could enhance the activation of the complement cascade. On the other hand, complement activation might lead to coagulation and fibrin deposition. *Ex vivo* as well as *in vitro* data show how complement proteins influence fibrin clot characteristics [84] and induce a prothrombotic/anti-fibrinolytic state [85–87]. Therefore, after the initial activation of the complement cascade by A β and tau, complement proteins could affect fibrin clot formation and induce a prothrombotic state in the AD brain. These mechanisms could be mutually reinforcing, and the bidirectional cross-talk between coagulation and the complement system could synergistically exacerbate AD pathology.

Fibrin(ogen) and the inflammatory response in AD

Microglial cells are the resident macrophages of the brain that become activated after an insult and release cytokines and free radicals. The presence of activated microglia progressively increases with AD pathogenesis [16]. They are found in and around A β plaques [19, 77], releasing a variety of cytokines and chemokines [88]. Although microglial cells are clearly involved in AD, their exact contribution to neuroprotection versus neurodegeneration is not clear. The activation of microglia might have a beneficial effect aiding in the clearance of plaques. However, as the disease progresses, the clearance system may be overwhelmed as microglia become dysfunctional and detrimental through the continuous release of inflammatory molecules [88].

In addition to its well-known function in hemostasis, fibrinogen also acts as a pro-inflammatory molecule. Fibrin(ogen) binds the integrin $\alpha_M\beta_2$ present in activated leukocytes, which is essential for the inflammatory response [89]. This role of fibrinogen is crucial in diseases such as atherosclerosis and rheumatoid arthritis, but it has also been

implicated in the inflammatory pathology related to neurological diseases, such as stroke, spinal cord injury, and multiple sclerosis [90].

Several pieces of evidence demonstrate a tight relationship between fibrinogen and inflammation in AD. A close association between fibrin(ogen) deposits and microglial clusters has been observed in the human AD brain [16, 19]. Moreover, results from our laboratory show that modulating fibrinogen levels in an AD mouse model dramatically influences not only the inflammatory response associated with this disorder, but also the neurovascular damage and BBB dysfunction [18, 91]. Ryu *et al*/demonstrated that decreasing fibrinogen levels prevents microglial activation and neuronal loss after hippocampal injection of A β in rats. They also showed that fibrinogen injection alone into the hippocampus induces microgliosis, BBB permeability, and neuronal death, which were all exacerbated when A β was co-injected with fibrinogen [19].

In AD, fibrin(ogen) is found deposited in the cerebral vessels and brain parenchyma, which may contribute to and promote neuroinflammation. Moreover, this inflammatory response in the brain is sustained, since fibrin(ogen) is not efficiently cleared from the brain when bound to A β and because hemostasis is altered in AD. This persistent fibrin(ogen) would therefore ultimately exacerbate an already active inflammatory response. It remains to be determined whether increased fibrinogen extravasation and deposition in the AD brain contribute to the neuronal damage associated with AD, or whether fibrinogen deposition is affected by genetic risk factors such as ApoE isoform. Another interesting question is whether blocking the A β -fibrinogen interaction would affect the various pathologies observed in AD.

Conclusion

We provide evidence suggesting that fibrin(ogen) and altered hemostasis play a fundamental role in AD physiopathology. In our model, which is summarized in the figure, the A β -fibrin(ogen) interaction promotes the deposition of both fibrin(ogen) and A β in the AD brain parenchyma and vessels and induces the formation of abnormal fibrin clots that are more resistant to degradation. Altered hemostasis further contributes to a prothrombotic environment in the AD brain and circulation, leading to persistent fibrin(ogen) deposits that promote neuroinflammation, blood vessel occlusion, and hypoperfusion. These events could eventually result in the vascular damage, synaptic dysfunction, neuronal death, and cognitive impairment observed in AD. Several lines of evidence support our hypothesis that fibrin(ogen) plays a critical role in AD pathogenesis: 1) high levels of fibrinogen in plasma increase the risk for dementia in humans; 2) pharmacological or genetic depletion of fibrinogen in AD mouse models lessens BBB dysfunction, neurovascular damage, neuroinflammation, and CAA pathology and improves cognitive function; 3) anticoagulant treatment in patients and AD mice showed improvement in memory or a slower cognitive decline compared to controls; 4) there is an association between stroke/microinfarcts and AD; and 5) fibrinogen in the cerebral spinal fluid has been identified as a useful biomarker to distinguish between AD and cognitively-normal or mildly demented patients [92, 93] and correlates with disease progression [94]. Given this evidence, it may be possible to use the presence of the A β -fibrinogen complex in plasma or cerebral spinal fluid as a biomarker for AD. Additionally, an inhibitor of the A β -fibrin(ogen) interaction might prove successful in slowing or reversing vascular deficits that contribute to AD pathogenesis. One of the advantages of this specific approach is that it might prevent the abnormal clotting provoked by A β without affecting physiological coagulation. Since AD is a multifactorial disease, we believe this approach could be used in combination with other strategies to treat the various pathologies associated with this disorder.

Acknowledgments

This work was supported by NIH grant NS050537, Thome Memorial Medical Foundation, Alzheimer's Drug Discovery Foundation, Mellam Family Foundation, May and Samuel Rudin Family Foundation, Litwin Foundation, and the Blanchette Hooker Rockefeller Fund. M.C.-C. was supported by the American Health Assistance Foundation. We thank the Alzheimer's Disease Research Center at Washington University (P50 AG05681) and the Harvard Brain Tissue Resource Center (PHS R24-MH 068855) for providing human brain tissue.

References

1. Humpel C. Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease? *Exp Gerontol.* 2011; 46:225–232. [PubMed: 21112383]
2. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. *Acta Neuropathol.* 2010; 120:287–296. [PubMed: 20623294]
3. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. *Lancet Neurol.* 2004; 3:184–190. [PubMed: 14980533]
4. Zlokovic BV. Neurodegeneration and the neurovascular unit. *Nat Med.* 2010; 16:1370–1371. [PubMed: 21135839]
5. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science.* 2002; 297:353–356. [PubMed: 12130773]
6. Wood H. Alzheimer disease: fibrinogen links amyloid with vascular dysfunction. *Nat Rev Neurol.* 2010; 6:413. [PubMed: 20718101]
7. Weisel JW. Fibrinogen and fibrin. *Adv Protein Chem.* 2005; 70:247–299. [PubMed: 15837518]
8. Mustard JF, Packham MA, Kinlough-Rathbone RL, Perry DW, Regoeczi E. Fibrinogen and ADP-induced platelet aggregation. *Blood.* 1978; 52:453–466. [PubMed: 96891]
9. Lominadze D, Dean WL, Tyagi SC, Roberts AM. Mechanisms of fibrinogen-induced microvascular dysfunction during cardiovascular disease. *Acta Physiologica.* 2010; 198:1–13. [PubMed: 19723026]
10. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. *Ann Intern Med.* 1993; 118:956–963. [PubMed: 8489110]
11. Xu G, Zhang H, Zhang S, Fan X, Liu X. Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. *Int J Clin Pract.* 2008; 62:1070–1075. [PubMed: 17916180]
12. van Oijen M, Witterman JC, Hofman A, Koudstaal PJ, Breteler MM. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. *Stroke.* 2005; 36:2637–2641. [PubMed: 16269641]
13. Thambisetty M, Simmons A, Hye A, Campbell J, Westman E, Zhang Y, Wahlund LO, Kinsey A, Causevic M, Killick R, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Spenger C, Lovestone S. Plasma biomarkers of brain atrophy in Alzheimer's disease. *PloS One.* 2011; 6:e28527. [PubMed: 22205954]
14. Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, Zmolodchikov D, Bhuvanendran S, Fenz KM, Strickland S. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. *Neuron.* 2010; 66:695–709. [PubMed: 20547128]
15. Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC, Vinters HV. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. *Eur J Clin Invest.* 2002; 32:360–371. [PubMed: 12027877]
16. Jantarantotai N, Schwab C, Ryu JK, McGeer PL, McLarnon JG. Converging perturbed microvasculature and microglial clusters characterize Alzheimer disease brain. *Curr Alzheimer Res.* 2010; 7:625–636. [PubMed: 20704556]
17. Lipinski B, Sajdel-Sulkowska EM. New insight into Alzheimer disease: demonstration of fibrin(ogen)-serum albumin insoluble deposits in brain tissue. *Alzheimer Dis Assoc Disord.* 2006; 20:323–326. [PubMed: 17132984]

18. Paul J, Strickland S, Melchor JP. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. *J Exp Med*. 2007; 204:1999–2008. [PubMed: 17664291]
19. Ryu JK, McLarnon JG. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. *J Cell Mol Med*. 2009; 13:2911–2925. [PubMed: 18657226]
20. Viggars AP, Wharton SB, Simpson JE, Matthews FE, Brayne C, Savva GM, Garwood C, Drew D, Shaw PJ, Ince PG. Alterations in the blood brain barrier in ageing cerebral cortex in relationship to Alzheimer-type pathology: a study in the MRC-CFAS population neuropathology cohort. *Neurosci Lett*. 2011; 505:25–30. [PubMed: 21970975]
21. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. *Microcirculation*. 2003; 10:463–470. [PubMed: 14745459]
22. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, Vitek MP, Hovanesian V, Stopa EG. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. *Neurobiol Aging*. 2007; 28:977–986. [PubMed: 16782234]
23. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci*. 2001; 98:8850–8855. [PubMed: 11438712]
24. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarccone T, Goate A, Mayo K, Perlmuter D, Coma M, Zhong Z, Zlokovic BV. Clearance of amyloid-beta by circulating lipoprotein receptors. *Nat Med*. 2007; 13:1029–1031. [PubMed: 17694066]
25. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. *J Clin Invest*. 2003; 112:1533–1540. [PubMed: 14617754]
26. Takechi R, Galloway S, Pallegage-Gamarallage MM, Lam V, Mamo JC. Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. *Prog Lipid Res*. 2010; 49:159–170. [PubMed: 19896503]
27. Weis SM. Vascular permeability in cardiovascular disease and cancer. *Curr Opin Hematol*. 2008; 15:243–249. [PubMed: 18391792]
28. Wardlaw JM, Sandercock PA, Dennis MS, Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? *Stroke*. 2003; 34:806–812. [PubMed: 12624314]
29. Tyagi N, Roberts AM, Dean WL, Tyagi SC, Lominadze D. Fibrinogen induces endothelial cell permeability. *Mol Cell Biochem*. 2008; 307:13–22. [PubMed: 17849175]
30. Patibandla PK, Tyagi N, Dean WL, Tyagi SC, Roberts AM, Lominadze D. Fibrinogen induces alterations of endothelial cell tight junction proteins. *J Cell Physiol*. 2009; 221:195–203. [PubMed: 19507189]
31. Nicoll JA, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller RO. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. *Neurobiol Aging*. 2004; 25:589–597. discussion 603–584. [PubMed: 15172734]
32. Thal DR, Griffin WS, de Vos RA, Ghebremedhin E. Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. *Acta Neuropathol*. 2008; 115:599–609. [PubMed: 18369648]
33. Vinters HV. Cerebral amyloid angiopathy. A critical review. *Stroke*. 1987; 18:311–324. [PubMed: 3551211]
34. Attems J, Jellinger K, Thal DR, Van Nostrand W. Review: sporadic cerebral amyloid angiopathy. *Neuropathol Appl Neurobiol*. 2011; 37:75–93. [PubMed: 20946241]
35. Thal DR, Capetillo-Zarate E, Larionov S, Staufenbiel M, Zurbuegg S, Beckmann N. Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. *Neurobiol Aging*. 2009; 30:1936–1948. [PubMed: 18359131]
36. Smith EE, Greenberg SM. Beta-amyloid, blood vessels, and brain function. *Stroke*. 2009; 40:2601–2606. [PubMed: 19443808]
37. Staffen W, Bergmann J, Schonauer U, Zauner H, Kronbichler M, Golaszewski S, Ladurner G. Cerebral perfusion (HMPAO-SPECT) in patients with depression with cognitive impairment

- versus those with mild cognitive impairment and dementia of Alzheimer's type: a semiquantitative and automated evaluation. *Eur J Nucl Med Mol Imaging*. 2009; 36:801–810. [PubMed: 19137294]
38. Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust WJ, Gorno-Tempini ML, Schuff N. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. *Radiology*. 2005; 234:851–859. [PubMed: 15734937]
 39. Klohs J, Baltes C, Princz-Kranz F, Ratering D, Nitsch RM, Knuesel I, Rudin M. Contrast-enhanced magnetic resonance microangiography reveals remodeling of the cerebral microvasculature in transgenic ArcAbeta mice. *J Neurosci*. 2012; 32:1705–1713. [PubMed: 22302811]
 40. Ahn HJ, Zamolodchikov D, Cortes-Canteli M, Norris EH, Glickman JF, Strickland S. Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. *Proc Natl Acad Sci*. 2010; 107:21812–21817. [PubMed: 21098282]
 41. Garcia-Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C, Frosch MP, Greenberg SM, Bacskai BJ. Cerebrovascular lesions induce transient beta-amyloid deposition. *Brain*. 2011; 134:3697–3707. [PubMed: 22120142]
 42. Zamolodchikov D, Strickland S. A β delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin. *Blood*. 2012; 119:3342–3351. [PubMed: 22238323]
 43. Lam CK, Yoo T, Hiner B, Liu Z, Grutzendler J. Embolus extravasation is an alternative mechanism for cerebral microvascular recanalization. *Nature*. 2010; 465:478–482. [PubMed: 20505729]
 44. Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Perego C, De Luigi A, Vergani C, De Simoni MG. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. *J Neurosci*. 2004; 24:4181–4186. [PubMed: 15115813]
 45. Timmer NM, van Dijk L, van der Zee CE, Kiliaan A, de Waal RM, Verbeek MM. Enoxaparin treatment administered at both early and late stages of amyloid beta deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Abeta levels. *Neurobiol Dis*. 2010; 40:340–347. [PubMed: 20600909]
 46. Ratner J, Rosenberg G, Kral VA, Engelsmann F. Anticoagulant therapy for senile dementia. *J Am Geriatr Soc*. 1972; 20:556–559. [PubMed: 5082125]
 47. Walsh AC. Anticoagulant therapy for Alzheimer's disease. *J Neuropsychiatry Clin Neurosci*. 1996; 8:361–362. [PubMed: 8854311]
 48. Walsh AC, Walsh BH, Melaney C. Senile-presenile dementia: follow-up data on an effective psychotherapy-anticoagulant regimen. *J Am Geriatr Soc*. 1978; 26:467–470. [PubMed: 701697]
 49. Barber M, Tait RC, Scott J, Rumley A, Lowe GD, Stott DJ. Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation. *J Thromb Haemost*. 2004; 2:1873–1878. [PubMed: 15550013]
 50. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. *Circulation*. 123:2363–2372. [PubMed: 21576658]
 51. Purandare N, Burns A. Cerebral emboli in the genesis of dementia. *J Neurol Sci*. 2009; 283:17–20. [PubMed: 19249797]
 52. Purandare N, Burns A, Morris J, Perry EP, Wren J, McCollum C. Association of cerebral emboli with accelerated cognitive deterioration in Alzheimer's disease and vascular dementia. *Am J Psychiatry*. 2012; 169:300–308. [PubMed: 22193532]
 53. Brundel M, de Bresser J, van Dillen JJ, Kappelle LJ, Biessels GJ. Cerebral microinfarcts: a systematic review of neuropathological studies. *J Cereb Blood Flow Metab*. 2012; 32:425–436. [PubMed: 22234334]
 54. Schneider JA, Boyle PA, Arvanitakis Z, Bienias JL, Bennett DA. Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons. *Ann Neurol*. 2007; 62:59–66. [PubMed: 17503514]

55. Cumming TB, Brodtmann A. Can stroke cause neurodegenerative dementia? *Int J Stroke*. 2011; 6:416–424. [PubMed: 21951407]
56. Bangen KJ, Delano-Wood L, Wierenga CE, McCauley A, Jeste DV, Salmon DP, Bondi MW. Associations between stroke risk and cognition in normal aging and Alzheimer's disease with and without depression. *Int J Geriatr Psychiatry*. 2010; 25:175–182. [PubMed: 19551707]
57. Furie B, Furie BC. Mechanisms of thrombus formation. *N Engl J Med*. 2008; 359:938–949. [PubMed: 18753650]
58. Mari D, Parnetti L, Coppola R, Bottasso B, Reboldi GP, Senin U, Mannucci PM. Hemostasis abnormalities in patients with vascular dementia and Alzheimer's disease. *Thromb Haemost*. 1996; 75:216–218. [PubMed: 8815562]
59. Gupta A, Watkins A, Thomas P, Majer R, Habubi N, Morris G, Pansari K. Coagulation and inflammatory markers in Alzheimer's and vascular dementia. *Int J Clin Pract*. 2005; 59:52–57. [PubMed: 15707465]
60. Bots ML, van Kooten F, Breteler MM, Slagboom PE, Hofman A, Haverkate F, Meijer P, Koudstaal PJ, Grobbee DE, Kluft C. Response to activated protein C in subjects with and without dementia. The Dutch Vascular Factors in Dementia Study. *Haemostasis*. 1998; 28:209–215. [PubMed: 10420068]
61. Peyvandi F, Garagiola I, Baronciani L. Role of von Willebrand factor in the haemostasis. *Blood Transfus*. 2011; 9(Suppl 2):s3–8. [PubMed: 21839029]
62. Stott DJ, Robertson M, Rumley A, Welsh P, Sattar N, Packard CJ, Shepherd J, Trompet S, Westendorp RG, de Craen AJ, Jukema JW, Buckley B, Ford I, Lowe GD. Activation of hemostasis and decline in cognitive function in older people. *Arterioscler Thromb Vasc Biol*. 2010; 30:605–611. [PubMed: 20032290]
63. Wolberg AS, Campbell RA. Thrombin generation, fibrin clot formation and hemostasis. *Transfus Apher Sci*. 2008; 38:15–23. [PubMed: 18282807]
64. Grammas P, Samany PG, Thirumangalakudi L. Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis. *J Alzheimers Dis*. 2006; 9:51–58. [PubMed: 16627934]
65. Yin X, Wright J, Wall T, Grammas P. Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease. *Am J Pathol*. 2010; 176:1600–1606. [PubMed: 20150433]
66. Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. *EMBO Rep*. 2000; 1:530–535. [PubMed: 11263499]
67. Fabbro S, Seeds NW. Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain. *J Neurochem*. 2009; 109:303–315. [PubMed: 19222708]
68. Melchor JP, Pawlak R, Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. *J Neurosci*. 2003; 23:8867–8871. [PubMed: 14523088]
69. Sevush S, Jy W, Horstman LL, Mao WW, Kolodny L, Ahn YS. Platelet activation in Alzheimer disease. *Arch Neurol*. 1998; 55:530–536. [PubMed: 9561982]
70. Ciabattini G, Porreca E, Di Febbo C, Di Iorio A, Paganelli R, Bucciarelli T, Pescara L, Del Re L, Giusti C, Falco A, Sau A, Patrono C, Davi G. Determinants of platelet activation in Alzheimer's disease. *Neurobiol Aging*. 2007; 28:336–342. [PubMed: 16442186]
71. Dale GL. Coated-platelets: an emerging component of the procoagulant response. *J Thromb Haemost*. 2005; 3:2185–2192. [PubMed: 16194197]
72. Prodan CI, Ross ED, Vincent AS, Dale GL. Coated-platelets correlate with disease progression in Alzheimer disease. *J Neurol*. 2007; 254:548–549. [PubMed: 17380246]
73. Prodan CI, Ross ED, Vincent AS, Dale GL. Rate of progression in Alzheimer's disease correlates with coated-platelet levels--a longitudinal study. *Transl Res*. 2008; 152:99–102. [PubMed: 18774538]
74. Tang K, Hynan LS, Baskin F, Rosenberg RN. Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. *J Neurol Sci*. 2006; 240:53–58. [PubMed: 16256140]
75. Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. *Immunology*. 2010; 129:154–169. [PubMed: 20561356]

76. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. *Circulation*. 2004; 109:2698–2704. [PubMed: 15184294]
77. McGeer EG, McGeer PL. Innate immunity in Alzheimer's disease: a model for local inflammatory reactions. *Molecular Interventions*. 2001; 1:22–29. [PubMed: 14993335]
78. Shen Y, Meri S. Yin and Yang: complement activation and regulation in Alzheimer's disease. *Prog Neurobiol*. 2003; 70:463–472. [PubMed: 14568360]
79. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P. Complement activation by beta-amyloid in Alzheimer disease. *Proc Natl Acad Sci*. 1992; 89:10016–10020. [PubMed: 1438191]
80. Shen Y, Lue L-F, Yang L-B, Roher A, Kuo Y-M, Strohmeier R, Goux WJ, Lee V, Johnson GVW, Webster SD, Cooper NR, Bradt B, Rogers J. Complement activation by neurofibrillary tangles in Alzheimer's disease. *Neurosci Lett*. 2001; 305:165–168. [PubMed: 11403931]
81. Yasojima K, Schwab C, McGeer EG, McGeer PL. Up-Regulated Production and Activation of the Complement System in Alzheimer's Disease Brain. *Am J Pathol*. 1999; 154:927–936. [PubMed: 10079271]
82. Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, Walker DG, Bradt B, Cooper NR, Rogers J. Molecular and Cellular Characterization of the Membrane Attack Complex, C5b-9, in Alzheimer's Disease. *Neurobiol Aging*. 1997; 18:415–421. [PubMed: 9330973]
83. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Brückner UB, Nilsson B, Gebhard F, Lambris JD, Huber-Lang M. Molecular Intercommunication between the Complement and Coagulation Systems. *J Immunol*. 2010; 185:5628–5636. [PubMed: 20870944]
84. Hess K, Alzahrani SH, Mathai M, Schroeder V, Carter AM, Howell G, Koko T, Strachan MW, Price JF, Smith KA, Grant PJ, Ajjan RA. A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. *Diabetologia*. 2012; 55:1103–1113. [PubMed: 21918806]
85. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. *Thromb Haemost*. 1997; 77:394–398. [PubMed: 9157602]
86. Wojta J, Huber K, Valent P. New aspects in thrombotic research: complement induced switch in mast cells from a profibrinolytic to a prothrombotic phenotype. *Pathophysiol Haemost Thromb*. 2003; 33:438–441. [PubMed: 15692257]
87. Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, Rafail S, Kartalis G, Sideras P, Lambris JD. A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation Pathways. *J Immunol*. 2006; 177:4794–4802. [PubMed: 16982920]
88. Solito E, Sastre M. Microglia function in Alzheimer's disease. *Front Pharmacol*. 2012; 3:14. [PubMed: 22363284]
89. Flick MJ, Du X, Witte DP, Jirouskova M, Soloviev DA, Busuttil SJ, Plow EF, Degen JL. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. *J Clin Invest*. 2004; 113:1596–1606. [PubMed: 15173886]
90. Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. *Semin Immunopathol*. 2012; 34:43–62. [PubMed: 22037947]
91. Cortes-Canteli M, Strickland S. Fibrinogen, a possible key player in Alzheimer's disease. *J Thromb Haemost*. 2009; 7(Suppl 1):146–150. [PubMed: 19630788]
92. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. *PLoS One*. 2011; 6:e18850. [PubMed: 21526197]
93. Vafadar-Isfahani B, Ball G, Coveney C, Lemetre C, Boocock D, Minthon L, Hansson O, Miles AK, Janciauskiene SM, Warden D, Smith AD, Wilcock G, Kalsheker N, Rees R, Matharoo-Ball B, Morgan K. Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. *J Alzheimers Dis*. 2012; 28:625–636. [PubMed: 22045497]
94. Lee JW, Namkoong H, Kim HK, Kim S, Hwang DW, Na HR, Ha SA, Kim JR, Kim JW. Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease. *BMC Neurol*. 2007; 7:14. [PubMed: 17565664]

Figure.

The scheme represents how the Aβ-fibrin(ogen) interaction may affect AD pathology. In an AD patient, Aβ interacts with fibrin(ogen) in the brain parenchyma (left panels) and cerebral blood vessels (middle panels). The Aβ-fibrin(ogen) interaction could also alter blood clot formation and degradation (right panels), which could be exacerbated by the prothrombotic environment present in AD. Together, these abnormalities would enhance inflammation and lead to vessel occlusion and hypoperfusion. These deleterious alterations would be sustained, since fibrin(ogen) persists longer in the AD brain due to its interaction with Aβ, and could eventually lead to neurovascular damage, neuronal dysfunction, and cognitive decline. Left panels show fibrin(ogen) and Aβ immunohistochemistry on frozen sections of the frontal cortex of an AD patient. Middle panels show fibrin(ogen) immunohistochemistry and Thioflavin S staining on paraffin-embedded sections of the frontal cortex of an AD patient [14]. Right panels show an *in vitro* fibrin clot in the presence of Aβ [14, 42].